| 03/18/2026 09:40 |
Announcement of Priority Review Designation by China's NMPA for F351, a Treatment for Chronic Hepatitis B Induced Liver Fibrosis |
| 03/13/2026 09:05 |
Disclosure of Statements Made at an Investor Conference of Gyre Therapeutics, Inc. |
| 03/04/2026 18:00 |
(Correction) Notice Regarding Differences in Non-Consolidated Financial Results |
| 03/04/2026 18:00 |
Notice Concerning Appointment of Directors |
| 03/03/2026 09:05 |
Notice Regarding the Execution of an Agreement for the Acquisition of Cullgen Inc. by Consolidated Subsidiary Gyre Therapeutics, Inc. |
| 02/13/2026 16:15 |
Notice Regarding the Postponement of the Disclosure of FY2026 Consolidated Earnings Forecast and Earnings Briefing |
| 02/13/2026 16:00 |
Notice Regarding Differences in Non-Consolidated Financial Results for the Fiscal Year Ended December 31, 2025 and the Previous Fiscal Year |
| 02/13/2026 16:00 |
Consolidated Financial Results for FY2025 (IFRS) |
| 02/12/2026 17:00 |
Questions from Investors and Answers |
| 01/23/2026 18:00 |
Announcement Regarding Revision of Full-Year Earnings Forecast and Expected Recognition of Losses |
| 01/09/2026 15:30 |
Notice Concerning Completion of Acquisition of Shares (Conversion into a Consolidated Subsidiary) of ZOO LABO, Inc. |
| 01/06/2026 08:30 |
Notice Regarding Completion of the Pre-NDA Meeting on the Regulatory Strategy for F351 Following Potential Eligibility for Priority Review |
| 12/22/2025 17:00 |
Notice Concerning Change in Consolidated Subsidiary (Termination of Equity Relationship) |
| 12/19/2025 08:45 |
Partial Amendment to Contractual Terms Relating to the Reverse Merger Transaction by Major Subsidiary Cullgen |
| 12/15/2025 08:30 |
Completion of Phase 1 Clinical Trial and Positive Results of CG001419, a Novel Non-Opioid Pain Product Candidate Developed by Key Subsidiary Cullgen |
| 11/14/2025 16:00 |
Consolidated Financial Results for Q3 FY2025 YTD (IFRS) |
| 11/14/2025 16:00 |
Q3 FY2025 Financial Results Corporate Presentation |
| 10/16/2025 10:00 |
Notice of Completion of Subject Enrollment in the Phase 3 Clinical Trial of Pirfenidone Capsule for the Treatment of Pneumoconiosis |
| 10/15/2025 08:45 |
Notice of Phase 3 Trial Results of F351 (Hydronidone) at AASLD-The Liver Meeting 2025 |
| 09/19/2025 08:30 |
Notice of Completion of Subject Enrollment in the Phase 1 Clinical Trial of Novel Non-Opioid Pain Product Candidate CG001419 Developed by Key Subsidia |
| 09/03/2025 17:30 |
[Delayed]Questions from Investors and Answers |
| 08/28/2025 16:00 |
Notice Regarding Appointment of Executive Officer |
| 08/15/2025 17:30 |
[Delayed] Q2 FY2025 Financial Results Corporate Presentation |
| 08/14/2025 16:00 |
Consolidated Financial Results for Q2 FY2025 YTD (IFRS) |
| 08/08/2025 17:00 |
Notice Regarding Adjustment of Exercise Price, etc. |
| 07/24/2025 17:30 |
Announcement Regarding Determination of Issue Price and Other Matters |
| 07/23/2025 16:00 |
Announcement Regarding Issuance of New Shares by way of International Offering |
| 06/17/2025 17:30 |
Results of Special Meeting of Pulmatrix, Inc., Cullgen's Reverse Merger Counterparty |
| 06/11/2025 09:50 |
Announcement of First Dosing in Phase 1 Clinical Trial of F230 for Pulmonary Arterial Hypertension (PAH) by Gyre Therapeutics |
| 06/05/2025 15:30 |
Announcement of the Launch of Etorel (Nintedanib Esilate Soft Capsules) by Gyre Pharmaceuticals |
| 06/02/2025 09:00 |
Notice Regarding Completion of Payment for Public Offering of New Shares by Gyre Therapeutics |
| 05/23/2025 18:02 |
Announcement Regarding Public Offering of New Shares by Gyre Therapeutics |
| 05/23/2025 18:01 |
To Patients Battling Hepatitis B, and to Our Supportive Shareholders |
| 05/23/2025 18:00 |
Regarding the Results of the Phase 3 Clinical Trial of Liver Fibrosis Treatment Drug F351 in China |
| 05/15/2025 16:00 |
Q1 FY2025 Financial Results Corporate Presentation |
| 05/15/2025 16:00 |
Consolidated Financial Results for Q1 FY2025 (IFRS) |
| 05/09/2025 16:00 |
Notice Concerning Finalized Issuance of Stock Acquisition Rights (Paid Stock Options) |
| 05/01/2025 11:00 |
GNI Group's view Regarding Gyre Therapeutics' Public Presentation |
| 04/24/2025 15:30 |
[Delayed]Notice Regarding Issuance of Stock Acquisition Rights (Paid-in Stock Options) |
| 04/14/2025 17:00 |
Corporate Governance Report |
| 04/08/2025 14:00 |
Notice Regarding Impact of U.S. Tariff Policy and Business Outlook |
